Miguel Villalona-Calero, MD, discusses interim data from a phase 1/2 investigation of KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma and highlights the ongoing evaluation of the agent’s safety.
Miguel Villalona-Calero, MD
Advertisement
Articles by Miguel Villalona-Calero, MD
Miguel Villalona-Calero, MD, discusses the unique mechanism of action of the CDK9 inhibitor KB-0742 in patients with relapsed/refractory solid tumors or non-Hodgkin lymphoma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
ASCO 2026 Ushers In a New Era for Pancreatic Cancer, Expands Targeted Therapy Options Across the GI Spectrum
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
FDA Flashback: Breast Cancer Decisions and News From May 2026
4
Dr Mathews on Updated Data From the RAINFOL-01 Trial in Advanced Ovarian Cancer
5